CompletedNot Applicable

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Japan1,200 participantsStarted 2022-04-15

Plain-language summary

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan * Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment Exclusion Criteria: * None

What they're measuring

Number of Subjects With Adverse Drug Reactions (ADRs)

Timeframe: Up to 52 weeks

Trial details

NCT IDNCT05262764

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-06-21

Results submitted2025-06-27

View on ClinicalTrials.gov More Heart Failure trials